 |
|
|
| |
Week 96 Safety and Efficacy by Gender and Race Subgroups in Treatment-Naïve HIV-1-Infected Patients in the Phase III ECHO and THRIVE Trials
|
| |
| |
Reported by Jules Levin
Womens Intl Workshop Jan 9-10 2012 Bethesda MD
Claudia Martorell, MD, MPH, FACP,1 Esteban Ribera, MD,2 Sharon Walmsley, MSc, MD,3 Simon Vanveggel, MSc4 and Katia Boven, MD5
1The Research Institute, Springfield, MA, USA; 2Hospital Vall D'Hebron, Barcelona, Spain; 3University Health Network, Toronto, ON, Canada; 4Tibotec BVBA, Beerse, Belgium; 5Tibotec Inc., Titusville, NJ, USA
|
| |
|
|
|
|
|
